A Follow-up Study of Neonates Receiving Extracorporeal Life Support in China

A Follow-up Study of Neonates Receiving Extracorporeal Life Support in China

Descriptive study of two-year follow-up outcomes of surviving neonates who are enrolled in the Chinese Neonatal Extracorporeal Life Support Registry (Chi-NELS) from 2022 to 2024.

This study aims to describe the six -month, one-year and two-year neurodevelopmental outcomes of survivors of neonatal ECLS treatment in the Chi-NELS. The study population will be neonates who receive ECLS support within 28 days of life and are enrolled in the Chi-NELS. These infants will be prospectively followed for two years. Mortality, growth, and neurodevelopmental outcomes will be assessed at six months, one year and two years.

Inclusion Criteria:

• Infants who receive extracorporeal life support (ECLS) at ≤28 days of life from 2022.1.1-2023.12.31
• Survive to the first ICU discharge

Exclusion Criteria:

• Infants who died during the ECLS hospitalization
• Parental refusal to follow-up